Results 261 to 270 of about 204,272 (330)

A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides

open access: yesEuropean Journal of Heart Failure, EarlyView.
Applying a simplified left atrial/natriuretic peptide (LA/NP) approach by combining enlarged LA volume indexed for height2 or elevated (N‐terminal pro) B‐type natriuretic peptide [(NT‐pro)BNP], using different cut‐off values for sinus rhythm (SR) and atrial fibrillation (AF) history.
Jerremy Weerts   +13 more
wiley   +1 more source

Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. [PDF]

open access: yesSci Rep
Iwane S   +13 more
europepmc   +1 more source

Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review

open access: yesEuropean Journal of Heart Failure, EarlyView.
This systematic review included seven studies that reported the outcomes of minimization or withdrawal of oral pharmacotherapy in chronic heart failure (HF) patients with improved myocardial function. There is a dearth of existing evidence, which supports only loop diuretic withdrawal and possibly carvedilol monotherapy.
Yuxiang Luo   +8 more
wiley   +1 more source

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Differences in baseline characteristics between major trials of intravenous (IV) iron therapy in heart failure. LVEF, left ventricular ejection fraction; SGLT2, sodium–glucose cotransporter 2. Aims Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ...
Stefan D. Anker   +44 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt   +16 more
wiley   +1 more source

Heart failure in patients with a systemic right ventricle: A multicentre study with long‐term follow‐up

open access: yesEuropean Journal of Heart Failure, EarlyView.
Risk of heart failure hospitalization in patients with a systemic right ventricle. AF, atrial fibrillation; AtrSO, atrial switch operation; ccTGA, congenitally corrected transposition of the great arteries; D‐TGA, dextro‐transposition of the great arteries; ECG, electrocardiogram; HF, heart failure; HR, hazard ratio; NYHA, New York Heart Association ...
Mohammad Mostafa Ansari Ramandi   +15 more
wiley   +1 more source

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...
Toru Kondo   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy